Please assess the completion status of the following clinical trial:

Trial Title: Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Randomized Study Arm Eligibility Criteria~General Inclusion Criteria~1. Subject is able and willing to comply with all assessments in the study.~2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.~3. Age of subject is greater than or equal to 18.~4. Rutherford Clinical Category 2, 3, or 4 of the target limb.~5. Estimated life expectancy \>1 year.~6. Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guideline.~7. Subject is intended to undergo treatment with Lithoplasty followed by DCB, or DCB with standard balloon pre-dilatation.~   Angiographic Inclusion Criteria~8. Target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery).~9. Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.~10. Target lesion is ≥70% stenosis by investigator via visual estimate.~11. Target lesion length is ≤180mm for lesions 70-99% stenosed. Target lesion can be all or part of the 180mm treated zone.~12. Chronic total occlusion, lesion length is ≤100mm of the total ≤180 mm target lesion.~13. Subject has at least one patent tibial vessel on the target leg with runoff to the foot, defined as no stenosis \>50%.~14. Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \<50mm in length.~General Exclusion Criteria~1. Rutherford Clinical Category 0, 1, 5 and 6.~2. Subject has active infection requiring antibiotic therapy.~3. Planned target limb major amputation (above the ankle).~4. History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure.~5. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter.~6. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.~7. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.~8. Subject has known allergy to urethane, nylon, or silicone.~9. Myocardial infarction within 60 days prior to enrollment.~10. History of stroke within 60 days prior to enrollment.~11. History of thrombolytic therapy within two weeks of enrollment.~12. Subject has acute or chronic renal disease defined as serum creatinine of \>2.5 mg/dL or \>220 umol/L, or on dialysis.~13. Subject is pregnant or nursing.~14. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.~15. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.~16. The use of specialty balloons, re-entry or atherectomy devices.~    Angiographic Exclusion Criteria~17. In-stent restenosis within 10mm of the target zone.~18. Lesions within 10mm of the ostium of the SFA or within 10mm of the ostium of the anterior tibial artery.~19. Evidence of aneurysm or thrombus in target vessel.~20. No calcium or mild calcium in the target lesion.~21. Target lesion within native or synthetic vessel grafts.~22. Subject has significant stenosis (\>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated.~23. Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to target site at the time of the index procedure.~24. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.~Subjects who do not meet the inclusion/exclusion criteria for the randomized study may satisfy the eligibility criteria for the observational study.~Observational Study Eligibility Criteria~Inclusion Criteria~1. Subjects intended to be treated with the Shockwave Medical Peripheral Lithoplasty® System for de-novo or restenotic lesions of the femoral, ilio-femoral, popliteal, and infra-popliteal arteries.~2. Subjects presenting with claudication or CLI by Rutherford Clinical Category 2,3,4,5, or 6 of the target limb.~3. Age of subject is \> 18.~4. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate, and has signed the approved study consent form.~5. Calcification is at least moderate, defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \<50mm in length.~Exclusion Criteria~1. Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion.~2. Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lithoplasty System followed by DCB (Type: EXPERIMENTAL): Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
- Medtronic IN.PACT (DCB) (Type: ACTIVE_COMPARATOR): Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete